{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:46:26Z","timestamp":1791985586345,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220211"],"award-info":[{"award-number":["220211"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Artemether-lumefantrine is the most widely used antimalarial treatment for uncomplicated Plasmodium falciparum malaria. Malaria predominantly affects populations in rural areas of tropical and subtropical regions. Drug resistance is a growing concern, and monitoring antimalarial efficacy remains crucial for detecting changes in treatment performance and tracking potential resistance trends. In this study, we present an efficient method for collecting blood samples in resource-limited settings, using dried blood spots on pre-treated filter paper, which enhances the stability of lumefantrine. This approach builds on previous methods by incorporating rapid sample processing through semi-automated punching robots for 96-well plate formats, quick sample cleanup via filtration through a phospholipid removal plate, and expedited analysis using liquid chromatography-tandem mass spectrometry (LC\u2013MS\/MS) with a turnaround time of just 2 min per sample. The method also achieves a significantly improved the lower limit of quantification of 15 ng of lumefantrine per ml of blood (i.e. LLOQ of 15 ng\/ml). A Phenomenex Luna-CN 50\u2009\u00d7\u20092 mm, 3 \u00b5m LC column was used, with a flow rate of 400 \u00b5l\/min and a mobile phase consisting of acetonitrile and ammonium formate buffer (10 mM, 0.5% formic acid) in a 67:33 (v\/v) ratio. The linear range for quantification spanned from 15 to 15,000 ng\/ml, based on three 3.2 mm punched discs from a 50 \u00b5l blood spot. Accuracy was within\u2009\u00b1\u200915% of the validation criteria, and precision was demonstrated by intra-assay variability of less than 7.2% and inter-assay variability of less than 12% across all concentration levels. The stability of lumefantrine in dried blood spots on pre-treated filter paper was demonstrated using a sample set obtained from another research group, which had been stored in the dark under low-humidity conditions for up to 16 years. The method showed no endogenous interference or interference from the concomitant drug artemether and is suitable for use in clinical trials.<\/jats:p>","DOI":"10.1186\/s12936-026-06048-y","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T03:05:05Z","timestamp":1784516705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lumefantrine quantification on pre-treated filter paper dried blood spots for clinical field trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Daniel","family":"Blessborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natpapat","family":"Kaewkhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Tarning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"6048_CR1","unstructured":"Malaria Key Facts. World Health Organization. 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/malaria. Accessed 4 Dec, 2025"},{"key":"6048_CR2","unstructured":"World malaria report 2025. Addressing the threat of antimalarial drug resistance [PDF]. Geneva: World Health Organization. 2025 [213]. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2025."},{"key":"6048_CR3","doi-asserted-by":"publisher","unstructured":"WHO guidelines for malaria [PDF]. Geneva: World Health Organization. 2024 [461]. https:\/\/doi.org\/10.2471\/B09146. Accessed 12 Mar, 2025","DOI":"10.2471\/B09146"},{"key":"6048_CR4","unstructured":"COARTEM Patient Information [PDF]. Novartis Pharmaceuticals Corporation. 2019. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/coartem.pdf. Accessed Nov 2024"},{"issue":"1","key":"6048_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0928-0987(99)00037-8","volume":"9","author":"D Colussi","year":"1999","unstructured":"Colussi D, Parisot C, Legay F, Lefevre G. Binding of artemether and lumefantrine to plasma proteins and erythrocytes. Eur J Pharm Sci. 1999;9(1):9\u201316.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"6048_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106482","volume":"59","author":"SR Sugiarto","year":"2022","unstructured":"Sugiarto SR, Page-Sharp M, Drinkwater JJ, Davis WA, Salman S, Davis TME. Pharmacokinetic properties of the antimalarial combination therapy artemether-lumefantrine in normal-weight, overweight and obese healthy male adults. Int J Antimicrob Agents. 2022;59(1):106482.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"6048_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202082","volume":"13","author":"L Huang","year":"2018","unstructured":"Huang L, Mwebaza N, Kajubi R, Marzan F, Forsman C, Parikh S, et al. Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients. PLoS ONE. 2018;13(8):e0202082.","journal-title":"PLoS ONE"},{"issue":"5","key":"6048_CR8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/S0035-9203(98)90917-8","volume":"92","author":"M van Vugt","year":"1998","unstructured":"van Vugt M, Ezzet F, Phaipun L, Nosten F, White NJ. The relationship between capillary and venous concentrations of the antimalarial drug lumefantrine (benflumetol). Trans R Soc Trop Med Hyg. 1998;92(5):564\u20135.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"6048_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jpba.2018.01.017","volume":"154","author":"J Gallay","year":"2018","unstructured":"Gallay J, Prod\u2019hom S, Mercier T, Bardinet C, Spaggiari D, Pothin E, et al. LC-MS\/MS method for the simultaneous analysis of seven antimalarials and two active metabolites in dried blood spots for applications in field trials: analytical and clinical validation. J Pharm Biomed Anal. 2018;154:263\u201377.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"6048_CR10","doi-asserted-by":"publisher","first-page":"7353","DOI":"10.1038\/s41467-025-62810-x","volume":"16","author":"M Okitwi","year":"2025","unstructured":"Okitwi M, Orena S, Tumwebaze PK, Katairo T, Taremwa Y, Byaruhanga O, et al. Changes in susceptibility of Plasmodium falciparum to antimalarial drugs in Uganda over time: 2019\u20132024. Nat Commun. 2025;16(1):7353.","journal-title":"Nat Commun"},{"issue":"14","key":"6048_CR11","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.4155\/bio.11.158","volume":"3","author":"N Lindegardh","year":"2011","unstructured":"Lindegardh N, Hanpithakpong W, Kamanikom B, Pattayaso J, Singhasivanon P, White NJ, et al. Quantification of dihydroartemisinin, artesunate and artemisinin in human blood: overcoming the technical challenge of protecting the peroxide bridge. Bioanalysis. 2011;3(14):1613\u201324.","journal-title":"Bioanalysis"},{"issue":"2","key":"6048_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jpba.2007.07.015","volume":"45","author":"D Blessborn","year":"2007","unstructured":"Blessborn D, Romsing S, Annerberg A, Sundquist D, Bjorkman A, Lindegardh N, et al. Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper. J Pharm Biomed Anal. 2007;45(2):282\u20137.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"6048_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jchromb.2008.11.002","volume":"876","author":"M Ntale","year":"2008","unstructured":"Ntale M, Ogwal-Okeng JW, Mahindi M, Gustafsson LL, Beck O. A field-adapted sampling and HPLC quantification method for lumefantrine and its desbutyl metabolite in whole blood spotted on filter paper. J Chromatogr B Anal Technol Biomed Life Sci. 2008;876(2):261\u20135.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"1","key":"6048_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5762","volume":"38","author":"BO Brooks","year":"2024","unstructured":"Brooks BO, Paganotti GM, Massele A, Sepako E, Adiukwu P, Sichilongo KF. A simple and rapid external standard calibration HPLC method for determination of lumefantrine in dried blood spot samples from malaria patients in Botswana. Biomed Chromatogr. 2024;38(1):e5762.","journal-title":"Biomed Chromatogr"},{"key":"6048_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jpba.2018.04.002","volume":"155","author":"MM Ippolito","year":"2018","unstructured":"Ippolito MM, Huang L, Siame M, Thuma P, Shapiro TA, Aweeka FT. Semi-quantitative measurement of the antimalarial lumefantrine from untreated dried blood spots using LC-MS\/MS. J Pharm Biomed Anal. 2018;155:241\u20136.","journal-title":"J Pharm Biomed Anal"},{"key":"6048_CR16","unstructured":"FDA. M10 Bioanalytical Method Validation and Study Sample Analysis U.S. Department of Health and Human Services, Food and Drug Administration. 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m10-bioanalytical-method-validation-and-study-sample-analysis."},{"key":"6048_CR17","unstructured":"FDA. Bioanalytical Method Validation, Guidance for Industry U.S. Department of Health and Human Services, Food and Drug Administration: FDA. 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf."},{"issue":"13","key":"6048_CR18","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1021\/ac020361s","volume":"75","author":"BK Matuszewski","year":"2003","unstructured":"Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS. Anal Chem. 2003;75(13):3019\u201330.","journal-title":"Anal Chem"},{"issue":"5","key":"6048_CR19","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jpba.2004.07.041","volume":"37","author":"N Lindegardh","year":"2005","unstructured":"Lindegardh N, Annerberg A, Blessborn D, Bergqvist Y, Day N, White NJ. Development and validation of a bioanalytical method using automated solid-phase extraction and LC-UV for the simultaneous determination of lumefantrine and its desbutyl metabolite in plasma. J Pharm Biomed Anal. 2005;37(5):1081\u20138.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"6048_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12936-018-2509-9","volume":"17","author":"NJ White","year":"2018","unstructured":"White NJ. Anaemia and malaria. Malar J. 2018;17(1):371.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-06048-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-06048-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-06048-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:59:25Z","timestamp":1791982765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-06048-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6048"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-06048-y","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"366"}}